| Title: |
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry |
| Authors: |
Salmanton-García, J.; Marchesi, F.; Koehler, P.; Weinbergerová, B.; olovi?, N.; Falces-Romero, I.; Buquicchio, C.; Farina, F.; van Praet, J.; Biernat, M.M.; Itri, F.; Prezioso, L.; Tascini, C.; Vena, A.; Romano, A.; Delia, M.; Dávila-Valls, J.; Martín-Pérez, S.; Lavilla Rubira, Esperanza; Ad?i?-vuki?evi?, T.; García-Bordallo, D.; López-García, A.; Criscuolo, M.; Petzer, V.; Fracchiolla, N.S.; Espigado, I.; Sili, U.; Meers, S.; Erben, N.; Cattaneo, C.; Tragiannidis, A.; Gavriilaki, E.; Schönlein, M.; Mitrovic, M.; Pantic, N.; Merelli, M.; Labrador, J.; Hernández-Rivas, J.-Á.; Glenthøj, A.; Fouquet, G.; del Principe, M.I.; Dargenio, M.; Calbacho, M.; Besson, C.; Kohn, M.; Gräfe, S.; Hersby, D.S.; Arellano, E.; Çolak, G.M.; Wolf, D.; Marchetti, M.; Nordlander, A.; Blennow, O.; Cordoba, R.; Mi?kovi?, B.; Mladenovi?, M.; Bavastro, M.; Limongelli, A.; Rahimli, L.; Pagano, L.; Cornely, O.A. |
| Publication Year: |
2023 |
| Subject Terms: |
Humans; Male; Middle Aged; Aged; Female; COVID-19; COVID-19 Drug Treatment; Ritonavir; SARS-CoV-2; Europe; Hematologic Neoplasms; Antiviral Agents; AS Lugo; CHULA |
| Description: |
Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, whereas molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir because it is associated with fewer drug-drug interactions and contraindications. A caveat for molnupiravir is the mode of action induces viral mutations. Mortality rate reduction with molnupiravir was less pronounced than that with nirmatrelvir/ritonavir in patients without haematological malignancy. Little is known about the comparative efficacy of the two drugs in patients with haematological malignancy at high-risk of severe COVID-19. Thus, molnupiravir and nirmatrelvir/ritonavir were compared in a cohort of patients with haematological malignancies. Methods: Clinical data from patients treated with molnupiravir or nirmatrelvir/ritonavir monotherapy for COVID-19 were retrieved from the EPICOVIDEHA registry. Patients treated with molnupiravir were matched by sex, age (±10 years), and severity of baseline haematological malignancy to controls treated with nirmatrelvir/ritonavir. Results: A total of 116 patients receiving molnupiravir for the clinical management of COVID-19 were matched to an equal number of controls receiving nirmatrelvir/ritonavir. In each of the groups, 68 (59%) patients were male; with a median age of 64 years (interquartile range [IQR] 53-74) for molnupiravir recipients and 64 years (IQR 54-73) for nirmatrelvir/ritonavir recipients; 56.9% (n=66) of the patients had controlled baseline haematological malignancy, 12.9% (n=15) had stable disease, and 30.2% (n=35) had active disease at COVID-19 onset in each group. During COVID-19 infection, one third of patients from each group were admitted to hospital. Although a similar proportion of patients in the two groups were vaccinated (molnupiravir n=77, 66% vs. ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States [2020-8223]; https://doi.org/10.1016/j.ijantimicag.2023.106952; https://portalcientifico.sergas.gal//documentos/651014670058624993e2c5b0; https://hdl.handle.net/20.500.11940/21748; 651014670058624993e2c5b0 |
| DOI: |
10.1016/j.ijantimicag.2023.106952 |
| Availability: |
https://hdl.handle.net/20.500.11940/21748; https://portalcientifico.sergas.gal//documentos/651014670058624993e2c5b0; https://doi.org/10.1016/j.ijantimicag.2023.106952 |
| Rights: |
Attribution 4.0 International (CC BY 4.0) ; http://creativecommons.org/licenses/by/4.0/ ; openAccess |
| Accession Number: |
edsbas.6EF4F75 |
| Database: |
BASE |